Clinical trial
A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Patients With Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS)
NCT05633407 is registered in ClinicalTrials.gov with argenx as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Patients With Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS)
- Lead sponsor
- argenx
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 23, 2022
- Completion date
- April 18, 2024
- Enrollment
- 53 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.